Biosearch Life, a biotechnology company focused on providing innovative solutions worldwide, has received authorization for registration of their probiotic strain Lactobacillus fermentum CECT5716 LC40, from the Family Planning and National Health Commission of the People’s Republic of China. This registration, granted after a long and arduous process, allows the inclusion of LC40 in infant formula milk manufactured in China.
Since 2011 Lactobacillus fermentum has been included in the list of authorized probiotics in China for food and food supplements. The Lactobacillus fermentum CECT5716 LC40 strain, is part of the range of Hereditum probiotics, protected by several patents and unique in origin, was isolated by Biosearch Life from breast milk. This specialized source of BiosearchLife strains, makes an outstanding candidate for use in infant nutrition, as, among other therapeutic effects, LC40 has been shown to significantly reduce digestive and respiratory infections in children. The safety of LC40 is guaranteed by the QPS (EFSA) and GRAS (FDA) classifications granted, and by the results of a long-term, three-year clinical trial for safety in children. In fact, the strain has had widespread use over several years in various children’s products in European countries.
The authorization of this registration is a great opportunity for Biosearch Life, as there are only eight strains authorized for this use in China, and this puts the company at the height of leading probiotic market companies at a key moment in the infant nutrition market in China. Coinciding with the registration of Lactobacillus fermentum CECT5716 LC40, the Chinese authorities have announced a change in the rules of marketing infant formula milk; this will involve restructuring the market, which is the largest in the world, and with great potential for growth. Biosearch Life believes that this authorization brings the company closer to its goal of becoming an international benchmark with its product range in the infant nutrition sector.
Biosearch Life provides innovation in healthy and natural ingredients integrating their research, development, production and marketing skills around three product platforms: Omega-3 (Eupoly-3®), Probiotics (Hereditum® and Botanical extracts (Exxentia®).
It provides comprehensive solutions to customers in more than thirty countries seeking maximum satisfaction with customized solutions and with a strong portfolio of over 200 products. The company strategy is based on constant innovation. Child nutrition, functional dairy products and women’s health are the sectors in which the company wants to be a benchmark.